Luye Pharma Group’s subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) in Antibody Therapeutic...
博优诺®(Bevacizumab Injection), an anticancer drug developed by Boan Biotech, a subsidiary of Luye Pharma Group, was launched in China on June 5, 2021. The first product from Boan Biotech’s pipe...
Luye Pharma Group announced today that its holding subsidiary, Boan Biotech, has signed an agreement with AstraZeneca China regarding the promotion rights to the anticancer drug 博优诺® (Bevacizumab I...
Boan Biotech，a holding subsidiary of Luye Pharma Group, announced that its biopharmaceutical drug 博优诺®(Bevacizumab Injection) has received marketing authorization from China’s National Medic...
Luye Pharma Group today announced that Nivolumab injection (LY01015) developed by the Group's holding subsidiary Boan Biotech, has obtained the approval from the China’s National Medical Pro...
Luye Pharma Group today announced that the phase I clinical trial for LY-CovMab, an innovative antibody for the treatment of COVID-19, has been completed in China, with good results in safety and tole...
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a tremendous threat to human health and the global economy. LY-CovMab is a human monoclonal neutraliz...
Boan Biotech, a holding subsidiary of Luye Pharma Group, will present an abstract about the preclinical data on its CD3/CEA bispecific antibody program at the American Association for Cancer Research ...
Luye Pharma Group announced that the clinical trial application for LY01015 (Nivolumab Injection) developed by the Group's subsidiary Boan Biotech, has been accepted by the Center for Drug Evaluat...
Luye Pharma Group today announced that Shandong Boan Biotechnology Co. Ltd. (Boan Biotech) has completed the first patient dosing in the phase Ⅲ clinical trial for LY09004 in China. As a key area for...
Follow me
鲁公网安备37069102000284